TD Cowen analyst Joseph Thome has maintained their bullish stance on VRDN stock, giving a Buy rating on November 9.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Joseph Thome’s rating is based on several promising developments within Viridian Therapeutics. The company is on the cusp of potentially significant milestones in 2026, including the anticipated approval of veligrotug for treating thyroid eye disease (TED) and the results from Phase III trials of VRDN-003. These advancements are bolstered by positive feedback from key opinion leaders, indicating strong potential for these therapies in the market.
Furthermore, Viridian’s lead candidate, veligrotug, has shown pivotal results that are at least on par with the current market leader, Tepezza, but with a more favorable administration profile. This could allow veligrotug to capture a significant share of the TED market. Additionally, VRDN-003 is designed for convenient at-home use, which may expand the treatment market and offer a competitive edge. Despite some regulatory and clinical risks, the company’s pipeline, including promising FcRn inhibitors, suggests a robust future, supporting the Buy rating.
According to TipRanks, Thome is a 5-star analyst with an average return of 11.4% and a 54.14% success rate. Thome covers the Healthcare sector, focusing on stocks such as United Therapeutics, AnaptysBio, and Alkermes.
In another report released on November 9, H.C. Wainwright also maintained a Buy rating on the stock with a $34.00 price target.